aTyr Pharma is a US-based biotherapeutics company that discovers and develops medicines using novel immunological pathways. Their lead therapeutic candidate is efzofitimod, which is being conduct clinical trials for treatment of interstitial lung diseases. The company also has a collaboration and license agreement with Kyorin Pharmaceutical Co.,Ltd. for development and commercialization of efzofitimod for ILDs in Japan.